Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Dartmouth Study Uses the Patient's Tumor to Form Vaccine
By Dross at 2010-11-29 22:45

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors. This dendritic cell (DC) vaccine, developed at Dartmouth and described in a research paper published this week in the journal Clinical Cancer Research, was used after surgical resection of metastaticterm tumors to try to prevent the growth of additional metastases.

read more | 2 comments | 2217 reads

Study: Prostate cancer treatment linked to higher rate of colon cancer | University of Michigan Health System
By Dross at 2010-11-16 03:48

NN ARBOR, Mich. — Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

read more | 2213 reads

Researchers pinpoint a new enemy for tumor-suppressor p53
By Dross at 2009-06-28 07:19

HOUSTON - Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.

The new protein, called Trim24, feeds p53 to a protein-shredding complex known as the proteasome by attaching targeting molecules called ubiquitins to the tumor suppressor, the team reported this week in the Proceedings of the National Academy of Sciences Online Early Edition.

read more | 2408 reads

Breakthrough optical technology to assess colon cancer risk, accuracy
By Dross at 2008-10-02 07:25

Researchers at NorthShore University HealthSystem (NorthShore) and Northwestern University have discovered that fiber optic technology can for the very first time effectively measure blood levels in the colonic lining (mucosa) in humans, thus having potential applications for analyzing risk of colon cancer.

The study appears in the October 2008 issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

The study used fiber optic technology to map microvascular blood content in patients during colonoscopy. The results provide the first indication that the early increase in blood supply (EIBS) is detectable in humans and that a high blood level mirrors proximity to neoplasia (process of tumor formation). The findings also suggest that this technology could be a valuable screening tool for enhancing polyp detection and could lead to improvements in colon cancer prevention.

read more | 1735 reads

Colon Cancer’s Potential for Metastasis Determined Early
By Dross at 2008-03-07 00:00

Some colon cancers are destined to spread to the liver and other parts of the body, whereas others are successfully treated by surgical removal of the tumor. Now, Howard Hughes Medical Institute investigators have found that the ability of a colon tumor to metastasize arises early in its development.

Those colon cancers that spread carry the ability to metastasize from the time they become cancerous, the researchers found. They don't need to acquire any new genetic mutations to become metastaticterm. The research also suggests that once a colon carcinomaterm develops, if it is going to spread outside the colon, it will do so in less than two years.

read more | 1 comment | 2247 reads

AGA supports new guidelines favoring tests that prevent colorectal cancer
By Dross at 2008-03-06 04:54

Bethesda, MD (March 5, 2008) – New consensus colorectal cancer guidelines released today state for the first time that the primary goal of colorectal cancer screening is cancer prevention. Previous guidelines have given equal weight to tests for detecting cancer and preventing cancer. By removing polyps from the large bowel, colonoscopy is the only screening test that also prevents colorectal cancer.

“Colorectal cancer prevention should be the primary goal of screening,” said Nicholas LaRusso, MD, AGAF, president, American Gastroenterological Association (AGA) Institute. “Detection and removal of precancerous lesions is essential to improve the health of Americans.”

read more | 1951 reads

New Genetic Barcoding Technique Identifies Dozens of Targets for Cancer Drugs
By Dross at 2008-02-01 02:59

Howard Hughes Medical Institute (HHMI) investigators have invented a quick and relatively inexpensive method for identifying genes that are indispensable for the growth and survival of colon and breast cancer cells.

The approach employs a massively parallel cellular system that simultaneously screens thousands of genes. Researchers can use information from the genetic screen to assess the relative impact of each gene on the growth and survival of tumor cells.

“We're examining as many genes as we can, and eventually every gene in the genome, to figure out which ones are deleterious to tumor cells.”
Stephen J. Elledge

read more | 2273 reads

Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
By Dross at 2008-01-29 01:19

Genomic Health, Inc. (NASDAQ:GHDX) today announced the results of studies that have identified genes that could help predict the likelihood of recurrence and chemotherapyterm benefit for early-stage (stage II and III) colon cancer. The company is conducting detailed analyses of these studies to select a final gene set for a clinical assay to quantify the risk of recurrence and likelihood of chemotherapy benefit, which will be evaluated in an independent validation study.

Results of the studies were presented January 26, 2008 at ASCO GI, the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium, in Orlando, Florida.

read more | 1719 reads

Picoplatin Safety Data in Colorectal Cancer
By Dross at 2008-01-28 02:33

Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company focused on oncology, today announced that it has presented safety data from a Phase 1 dose-escalation study of picoplatin, the Company's lead product candidate, at the 2008 Gastrointestinal Cancers Symposium, a meeting of the American Society of Clinical Oncology (ASCO) which is being held in Orlando, Fla.

The poster presentation included safety data from a Phase 1 study of picoplatin in combination with 5-fluorouraciltermtermtermterm (5FU) and leucovorintermterm (LV) as a first-line treatment for metastaticterm colorectal cancer (mCRC). The Phase 1 study seeks to establish the maximum tolerated dose of picoplatin and provide information on the safety of picoplatin when combined with 5FU and LV for the treatment of colorectal cancer. Promising safety data observed from the study to date formed the basis for further development of picoplatin in our ongoing Phase 2 trial in mCRC.

read more | 2183 reads

TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
By Dross at 2008-01-25 21:12

Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer. New data generated by Naofumi Mukaida and colleagues at Kanazawa University, Japan, identified a central role for the soluble factor TNF-alpha in the development of colon cancer in mice in which inflammation of the bowel was induced by administration of azoxymethane (AOM) followed by repeated dextran sulfate sodium (DSS) ingestion. Expression of TNF-alpha was increased in the colon of normal mice treated with AOM and DSS and this was followed by the development of tumors in the colon. Mice lacking one of the receptors for TNF-alpha and mice treated with an antagonist of TNF-alpha were markedly protected from the effects of treatment with AOM and DSS, developing less inflammation of the colon and fewer tumors in the colon. As suggested by the authors, and by Ezra Burstein and Eric R. Fearon in an accompanying commentary, these data provide clear rationale for the idea that drugs antagonizing TNF-alpha (such as those used to treat individuals with rheumatoid arthritis) might be useful in reducing the risk of colon cancer in individuals with ulcerative colitis.

read more | 2844 reads

SGX Initiates Phase I Trials for SGX523 for Breast, Colon, Prostate
By Dross at 2008-01-17 02:02

SGX Pharmaceuticals, Inc. (NASDAQ:SGXP) today announced that it has opened enrollment in two Phase I studies, with the first patient being treated on January 14, 2008. The Phase I studies are designed to evaluate the safety, tolerability and pharmacokinetic profile of SGX523, an internally developed, orally-bioavailable, small molecule inhibitor of the cMET receptor tyrosine kinase.

The Phase I clinical trials are open-label, dose escalation studies of SGX523 administered orally to patients with advanced cancer who have either failed standard therapy or for whom no standard therapy exists. The studies are designed to explore two dosing regimens in parallel. The continuous dosing trial will have continuous uninterrupted twice daily dosing with patients being evaluated every 28 days for continuation of treatment. The intermittent dosing schedule will implement twice daily dosing on a 14 days on/7 days off therapy schedule, cycling every 21 days. In both protocols, patients may continue on therapy for up to 12 months as determined by the patient's response and tolerance to SGX523.

read more | 2350 reads

Colon cancer risk in US traced to common ancester
By Dross at 2008-01-03 02:42

Salt Lake City — A married couple who sailed from England to America around 1630 may be the ancestors of hundreds of people alive today who are at risk for a hereditary form of colon cancer.

Researchers from Huntsman Cancer Institute (HCI) at The University of Utah have discovered a founder mutation—a mutation that has been traced from many individuals in the present-day population back to a common ancestor—which may contribute to a significant percentage of colon cancer cases in the United States.

An article reporting the finding was published today in Clinical Gastroenterology and Hepatology.

read more | 2124 reads

DNA methylation shown to promote development of colon tumors
By Dross at 2007-12-02 07:09

CAMBRIDGE, Mass. (December 1, 2007) — Damaged or defective genes have long been known to be the cause of some cancers. Over the past decade, however, scientists have discovered that even healthy genes can be switched on or off and can cause cancer without any changes in the underlying DNA sequence—although how this happens has remained poorly understood.

Researchers in the laboratory of Whitehead Member Rudolf Jaenisch now have established a direct causal connection between hypermethylation (the accumulation of too many methyl molecules on regions of DNA) and the development of colon tumors in mice.

read more | 1 comment | 2044 reads

Increased glucose level is a strong risk factor for colorectal cancer
By Dross at 2007-11-05 05:16

Bethesda, MD (November 1, 2007) – Diabetes is a very common illness that affects more than 20 million people in the U.S. and it is estimated an additional 54 million Americans have pre-diabetes, a condition that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 diabetes. Therefore, it is important to determine whether glucose and insulin levels are associated with a higher risk of colon polyps, the precursor lesions to colon cancer. According to the results of a study published in Gastroenterology, patients with high levels of insulin and glucose are at increased risk of developing recurrent colorectal adenomas, or tumors, with elevated glucose providing the strongest risk factor for recurrence of these lesions.

read more | 2561 reads

Tablet is better all round for cancer patients
By Dross at 2007-10-09 01:24

A drug to treat colon cancer is proving much more convenient than traditional chemotherapyterm, has fewer side effectsterm - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

“Standard chemotherapy can be incredibly disruptive to people’s lives,” said Prof Professor Chris Twelves of the University of Leeds, who led the research. “Patients visit hospital five days a week for the injections and then have three weeks off before returning to hospital for the next course – and the side effects can be unpleasant.”

The oral chemotherapy drug Xelodaterm (capecitabinetermterm) offers fewer side-effects and less time in hospital – and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy (the Mayo Clinic regimen).

read more | 6 comments | 2254 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 04:50 PM.